📊 INBX Key Takeaways
Is Inhibrx Biosciences, Inc. (INBX) a Good Investment?
Inhibrx exhibits severe financial distress with negative stockholders' equity of -$21M, mounting operating losses (-$30.9M) that are worsening relative to minimal revenue ($1.3M), and negative free cash flow of -$38M annually. While the company possesses adequate cash runway (~4 years), the fundamentals reveal unsustainable unit economics and deteriorating financial health that requires near-term profitability or capital restructuring.
Fundamentals are extremely weak: minimal revenue with rapidly widening losses, deeply negative margins, and a very high debt-to-equity ratio on a thin equity base. While liquidity appears solid with substantial cash and a strong current ratio, the operating cash burn approximates the cash balance, implying a short runway without material revenue inflection or new financing. Absent clear evidence of near-term monetization, dilution or balance-sheet stress is likely.
Inhibrx Biosciences, Inc. Key Strengths (INBX)
- Strong liquidity position with $161.7M cash providing 4+ years of operational runway
- Exceptional revenue growth rate of 550% YoY indicating early commercial traction despite minimal absolute revenue
- Capital-efficient operations with zero capital expenditures, suggesting focused R&D spending
- Strong liquidity with $124.22M cash and 3.93x current ratio
- Asset-light model with negligible capex
- High YoY revenue growth off a small base (+550%)
INBX Stock Risks: Inhibrx Biosciences, Inc. Investment Risks
- Negative stockholders' equity of -$21M indicates technical insolvency and balance sheet deterioration
- Net losses worsening YoY (-108.3% decline) with operating margin of -2379%, demonstrating accelerating cash burn unsustainable without profitability
- Liabilities exceed total assets by $21M with $175M long-term debt burden; high leverage with negative interest coverage and no clear path to debt servicing from operations
- Severe, worsening unprofitability (operating and net margins below -10,000%)
- High leverage (12.58x debt/equity) and thin equity base
- Large operating cash burn (-$129.79M) implying limited runway and potential dilution
Key Metrics to Watch
- Operating cash flow trajectory and monthly cash burn rate to assess runway duration
- Revenue growth sustainability and path to gross profitability given current 550% growth rate
- Stockholders' equity recovery timeline and whether debt restructuring or capital raise is required
- Operating cash flow (TTM)
- Cash & equivalents
Inhibrx Biosciences, Inc. (INBX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.46x current ratio provides a solid financial cushion.
INBX Profit Margin, ROE & Profitability Analysis
INBX vs Healthcare Sector: How Inhibrx Biosciences, Inc. Compares
How Inhibrx Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Inhibrx Biosciences, Inc. Stock Overvalued? INBX Valuation Analysis 2026
Based on fundamental analysis, Inhibrx Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Inhibrx Biosciences, Inc. Balance Sheet: INBX Debt, Cash & Liquidity
INBX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Inhibrx Biosciences, Inc.'s revenue has declined by 28% over the 5-year period, indicating business contraction. The most recent EPS of $112.62 reflects profitable operations.
INBX Revenue Growth, EPS Growth & YoY Performance
INBX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$28.7M | $-2.28 |
| Q2 2025 | $100.0K | -$28.7M | $-1.85 |
| Q1 2025 | N/A | -$43.3M | $-2.80 |
| Q3 2024 | N/A | -$43.9M | $-2.84 |
| Q2 2024 | $30.0K | -$47.1M | $-4.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Inhibrx Biosciences, Inc. Dividends, Buybacks & Capital Allocation
INBX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Inhibrx Biosciences, Inc. (CIK: 0002007919)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INBX
What is the AI rating for INBX?
Inhibrx Biosciences, Inc. (INBX) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 79% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INBX's key strengths?
Claude: Strong liquidity position with $161.7M cash providing 4+ years of operational runway. Exceptional revenue growth rate of 550% YoY indicating early commercial traction despite minimal absolute revenue. ChatGPT: Strong liquidity with $124.22M cash and 3.93x current ratio. Asset-light model with negligible capex.
What are the risks of investing in INBX?
Claude: Negative stockholders' equity of -$21M indicates technical insolvency and balance sheet deterioration. Net losses worsening YoY (-108.3% decline) with operating margin of -2379%, demonstrating accelerating cash burn unsustainable without profitability. ChatGPT: Severe, worsening unprofitability (operating and net margins below -10,000%). High leverage (12.58x debt/equity) and thin equity base.
What is INBX's revenue and growth?
Inhibrx Biosciences, Inc. reported revenue of $1.3M.
Does INBX pay dividends?
Inhibrx Biosciences, Inc. does not currently pay dividends.
Where can I find INBX SEC filings?
Official SEC filings for Inhibrx Biosciences, Inc. (CIK: 0002007919) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INBX's EPS?
Inhibrx Biosciences, Inc. has a diluted EPS of $-2.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is INBX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Inhibrx Biosciences, Inc. has a C grade with 79% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is INBX stock overvalued or undervalued?
Valuation metrics for INBX: ROE of N/A (sector avg: 15%), net margin of -2,572.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is INBX's AI grade for 2026?
Our dual AI analysis gives Inhibrx Biosciences, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INBX's free cash flow?
Inhibrx Biosciences, Inc.'s operating cash flow is $-38.0M, with capital expenditures of $0.0. FCF margin is -2,925.1%.
How does INBX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,572.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 6.46 (avg: 2).